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Angiotensin converting enzyme inhibitor ACEI-induced angioedema of the intestine is a rare occurrence and often unrecognized
complication of ACEI. We present a case of a 45-year-old Hispanic female with angioedema of the small bowel progressing to
facial and oral pharyngeal angioedema. Patients are typically middle-aged females on ACEI therapy who present to the emergency
department with abdominal pain, nausea, vomiting, and diarrhea. This is a diagnosis of exclusion, and physicians must have a
high index of suspicion to make the diagnosis. Symptoms typically resolve within 24–48 hours after ACE inhibitor withdrawal.
Recognizingthesesignsandsymptoms,anddiscontinuingthemedication,cansaveapatientfromunnecessary, costly,andinvasive
procedures.
1.Introduction
Angioedemaofthefaceandoralpharynxisawell-recognized
complication of ACE inhibitor therapy. These medications
can also cause angioedema of the bowel and may present
a diagnostic dilemma to the emergency physician. Patients
typically present with a complaint of abdominal pain
with or without vomiting and diarrhea. Workup is usually
nondiagnostic including leukocytosis and nonspeciﬁc bowel
wall thickening on CT scan. Therapy consists of withdrawal
of the medication. This is a diagnosis of exclusion, and
physicians must have a high index of suspicion. Making the
diagnosis can prevent patients from exposure to costly and
invasive procedures.
2.CaseReport
A 45-year-old Hispanic female presented to the emergency
department with a chief complaint of severe abdominal pain
forthelastseveraldaysthatprogressedtoseverepainoverthe
last 24 hours. Approximately one week ago, the patient was
evaluated at another facility for a complaint of abdominal
pain. Lab tests showed an elevated lipase, and the patient
was diagnosed with pancreatitis. She was discharged home
and instructed to follow a clear liquid diet and advance as
tolerated.
The patient’s past medical history was signiﬁcant for
hypertension, type 2 diabetes, chronic renal failure requiring
dialysis, and the recent diagnosis of pancreatitis. Her medi-
cations included enalapril/hydrochlorothiazide, hydralazine,
clonidine, metoprolol, metoclopramide, promethazine, mir-
tazapine, pantoprazole, insulin NPH/regular 70/30, alprazo-
lam, and zolpidem.
On initial evaluation, the patient was complaining of
severaldaysofsharp,crampyabdominalpainworseningover
the 24 hours prior to arrival. She complained of nausea,
vomiting, and watery diarrhea for the past day. She denied
fever, chills, dizziness, weakness, headache, chest pain, or
shortness of breath. She denied blood in her emesis, stool, or
urine. The remainder of the review of systems was negative.
On initial physical exam, vital signs were signiﬁcant
for hypertension (175/86) and mild tachycardia (107). The
patient appeared to be in acute distress secondary to pain.
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edema, erythema, or exudates, and neck was supple with
full range of motion. Her lungs were clear to auscultation
bilaterally. Cardiac exam was signiﬁcant for tachycardia
with a regular rhythm, no murmurs, rubs, or gallops.
The patient’s abdomen was diﬀusely tender and worse in
the mid-epigastric and periumbilical region. She had no
peritoneal signs, and rectal exam was hemoccult negative.
The remainder of her physical exam was unremarkable.
Initial labs were signiﬁcant for an elevated white blood
cell count of 19.8K/UL with a left shift, and the rest of
the hemogram was normal. Her metabolic panel revealed a
BUN of 29mg/dL and creatinine of 5.8mg/dL (which was
consistent with her baseline). Serum glucose was 182mg/dL,
amylase slightly elevated at 203U/L (normal 36–128U/L),
lipase 43U/L (normal 10–51U/L), and liver function tests
were normal.
CT scan of the abdomen and pelvis was limited due to
thelackofIV contrastwith no signiﬁcant ﬁndings otherthan
mild edema of the small bowel, with No pancreatic swelling,
fat stranding, ﬂuid collection, free ﬂuid in the abdomen,
lymphadenopathy, or masses.
The patient was given multiple doses of hydromorphone
during her stay in the emergency department, with only
minimal improvement of her pain. The patient was reeval-
uated on several occasions with no change in her physical
exam. Shortly after returning from CT, the patient began
complaining of diﬃculty swallowing and mild shortness
of breath. Upon reevaluation at that time, the patient
was found to have diﬀuse swelling of her face, neck, lips,
oral pharynx, and tongue. The patient required emergent
ﬁberoptic intubation and was admitted to the intensive care
unit. During her hospitalization, C1 esterase inhibitor and
complement levels were all within normal limits.
The patient was diagnosed with ACEI angioedema of the
oralpharynxandsmallintestine.TheACEIwasdiscontinued
at the time of admission. The swelling improved, and she
was extubated after 48 hours. The patient’s abdominal pain
resolved, and she was discharged home with instructions to
avoid ACEI in the future. At followup visits over the next six
months, the patient’s abdominal pain had not returned (see
Figures 1 and 2).
3.Discussion
After review of the English literature, we were able to ﬁnd
21 documented cases of ACEI-induced angioedema of the
bowel [1–10]. Patients typically present with unexplained
abdominal pain despite extensive evaluation [1, 2]. The
patient in this case initially presented with abdominal pain
due to angioedema of the bowel. While in the emergency
department, she progressed to angioedema of the face
and oral pharynx, which is a rapid and atypical onset of
angioedema from ACEI.
Pancreatitis, obstruction, mesenteric ischemia, infection,
cholecystitis among other abdominal emergencies, and C1
esterase inhibitor deﬁciency all need to be considered in the
diﬀerential. Although the CT of the abdomen and pelvis was
done without IV and oral contrast, which is recommended
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tofully appreciatepathologyofthepancreas, itdidnotreveal
any signs of pancreatitis. The patient’s labs and CT scan were
not consistent with a diagnosis of pancreatitis, obstruction,
or acute infection. C1 esterase inhibitor deﬁciency was ruled
outduring heradmission. Asher facial angioedema resolved,
so did her abdominal pain. The abdominal pain did not
return after discontinuing the ACE inhibitor, leading to this
diagnosis of exclusion. At 6-month followup, the patient
remained free of abdominal pain.
Approximately 30% of all ED visits for angioedema are
from ACEI, while the annual rate of ED visits for ACEI-
induced angioedema is 0.7 per 10,000 [11, 12]. Angioedema
is asymmetrical nonpitting edema of the skin or mucus
membrane and a well-documented side eﬀect of ACEI
[13]. ACEI-induced angioedema typically aﬀects the face,
eyelids, lips, tongue, neck, and pharynx, while urticaria or
pruritis is seen only rarely [11, 13–17]. These adverse eﬀects
commonly present within the ﬁrst 4 weeks after initiation of
therapy and have not shown to be dose related or caused
by one particular ACEI [13–16]. No deﬁnitive predisposing
factors have been identiﬁed although the current literatureCase Reports in Medicine 3
suggests that patients with a history of either hereditary or
idiopathic angioedema are at an increased risk for ACEI-
induced angioedema [13, 15, 16]. Japanese patients have a
lower incidence of angioedema from ACEI while several case
reports have shown that patients of African origin have a
signiﬁcantly increased relative risk [13, 14, 18, 19].
The mechanism of action by which ACEI causes
angioedema is not fully understood, but it is theorized
to be from a biochemical rather than immunological
reaction [16]. ACE converts angiotensin I to angiotensin
II while also inactivating bradykinin. Increased levels of
bradykinin, along with other mediators, are responsible for
the angioedema reaction [13, 15, 16, 20]. Bradykinin causes
vasodilatation and increased vascular permeability, thereby
leading to angioedema. Some studies suggest that patients
with a deﬁciency of aminopeptidase-P, another enzyme that
catabolizes bradykinin, are at an increased risk of developing
of angioedema from ACEI [13, 17, 20].
ACE inhibitor-induced angioedema of the intestines is a
diagnosisthatshould beconsideredin any patientpresenting
withunexplainedabdominalpainwhileonanACEinhibitor.
The incidence of ACE inhibitor-induced angioedema is low
(0.1%–0.2%) with a small fraction of those representing
angioedemaofthebowel[1–4].However,theexactincidence
is unknown and is likely underdiagnosed [1, 4]. ACE
inhibitor angioedema of the intestine is more common in
females, with an averageageof 48years, suggesting a possible
sex-linked or hormonal etiology [4, 9]. Common symptoms
include abdominal pain, vomiting, diarrhea, and ascites
[3–5]. Symptoms typically present within 24–48 hours of
initiation of an ACE inhibitor, but there are case reports of
facial angioedema 7 years after initiation of therapy [6]a n d
bowel angioedema 9 months after initiation of therapy [3].
ThemanagementofACEIangioedemashouldbeprompt
and aggressive with careful attention to airway management.
Treatment can range from simple discontinuation of ACEI
therapy to intubation and vasopressors, depending on the
severity of the reaction. Angioedema of the intestine is
reversible with cessation of the medication. Many of the
patients discussed in the literature underwent invasive pro-
cedures including endoscopy, intestinal biopsy, exploratory
laparotomy, and bowel resection, before a diagnosis of ACE
inhibitor induced angioedema was made [1, 3, 4, 9]. Swift
recognition is necessary to prevent unwarranted procedures,
surgical intervention, or potentially death. Symptoms typi-
callyresolvewithin24–48hoursafterdiscontin uingtheA CEI
and continue to improve over the next 1 to 2 months [2, 10].
4.Conclusion
ACE inhibitor angioedema is a rare occurrence with intesti-
nal involvement being less common. Unfortunately there is
no speciﬁc test that can be used to diagnose the condition.
Failure to make the correct diagnosis can place patients at
increased riskofadverseoutcomesduetoinvasivetestingand
procedures. While there does appear to be a greater risk of
occurrence early in therapy, angioedema can present at any
timeandthuswhentreatinganypatientwithabdominalpain
use of ACEI therapy should be considered in the diﬀerential
diagnosis.
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